Financial Data and Key Metrics Changes - The company eliminated over $1.1 billion of debt through a financial reorganization, allowing a refocus on investment and execution for the future [25] - Total revenue in Q4 was $163 million, down 12% year-over-year, with a 32% growth in clinical revenue and a 17% decline in behavioral revenue [30] - Adjusted EBITDA for Q4 was $18 million, reflecting an adjusted EBITDA margin of 11.1% [32] - Monthly subscription revenue per average subscriber (ARPU) increased 8% year-over-year to $18.73 in Q4 [29] Business Line Data and Key Metrics Changes - End-of-period clinical subscribers were 130,000 at the end of Q4, with expectations to reach approximately 200,000 by the end of Q1, indicating roughly 100% year-over-year growth [26] - End-of-period behavioral subscribers were 2.6 million at the end of Q4 2025, with expectations to decline to approximately 2.45 million by the end of Q1, a decline of about 26% year-over-year [28] - The clinical business has a significantly higher ARPU, over four times that of the behavioral business [29] Market Data and Key Metrics Changes - Approximately 10 million Americans are estimated to be on GLP-1 medications, with projections of 25 to 50 million by 2030 [8] - The company reported a 30% increase in awareness of its Med+ offering following marketing efforts, indicating a successful repositioning of the brand [16] Company Strategy and Development Direction - The company is transitioning from a behavioral subscription model to an integrated weight health ecosystem that includes medication access and clinical care [9] - The focus is on creating a deeply engaging end-to-end member experience and innovating to capitalize on new technologies [11] - The strategy includes increasing levels of existing member migration across the portfolio and re-engaging lapsed behavioral members into Core+ and Med+ [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to succeed and emphasized the importance of integrating clinical and behavioral support for long-term member outcomes [42] - The company is aware of the challenges posed by the growing adoption of GLP-1 medications and is adapting its behavioral business accordingly [20] - For fiscal year 2026, the company expects revenue to be in the range of $620 million to $635 million and adjusted EBITDA to be in the range of $105 million to $115 million [37] Other Important Information - The company has modernized its technology infrastructure and is focused on building a robust foundation for future growth and innovation [12] - Marketing expenses in Q4 were 40% of revenue, reflecting increased efforts to raise awareness of the Med+ offering [31] Q&A Session Summary Question: Changes in demand for weight loss medications - Management noted a consistent trend of increasing consumer interest and adoption of GLP-1 medications, particularly with the introduction of lower-priced oral options like the Wegovy pill [40][41] Question: Profile of new members and demographics - Management indicated that 50% of new Med+ members are new to the brand, with efforts to reposition the brand as a leader in medically-centric weight health [48][49] Question: Marketing strategy and demographics - The company is seeing younger members starting to come into the brand and is focused on expanding demographics over time [56][58] Question: Pricing strategy and promotional activity - Management discussed a shift in pricing strategy allowing members to renew long-term commitments, which may impact ARPU but is expected to stabilize over time [67][70] Question: B2B initiative and growth expectations - The company is optimistic about its B2B pipeline and is expanding partnerships, particularly with UnitedHealth Group, to enhance employer relationships [72][75]